Substrate-guided optimization of the syringolins yields potent proteasome inhibitors with activity against leukemia cell lines
Author(s)
Totaro, Kyle A.; Barthelme, Dominik; Simpson, Peter T.; Sello, Jason K.; Sauer, Robert T.
DownloadSauer_Substrate-guided.pdf (982.4Kb)
PUBLISHER_CC
Publisher with Creative Commons License
Creative Commons Attribution
Terms of use
Metadata
Show full item recordAbstract
Natural products that inhibit the proteasome have been fruitful starting points for the development of drug candidates. Those of the syringolin family have been underexploited in this context. Using the published model for substrate mimicry by the syringolins and knowledge about the substrate preferences of the proteolytic subunits of the human proteasome, we have designed, synthesized, and evaluated syringolin analogs. As some of our analogs inhibit the activity of the proteasome with second-order rate constants 5-fold greater than that of the methyl ester of syringolin B, we conclude that the substrate mimicry model for the syringolins is valid. The improvements in in vitro potency and the activities of particular analogs against leukemia cell lines are strong bases for further development of the syringolins as anti-cancer drugs.
Date issued
2015-07Department
Massachusetts Institute of Technology. Department of BiologyJournal
Bioorganic & Medicinal Chemistry
Publisher
Elsevier
Citation
Totaro, Kyle A. et al. “Substrate-Guided Optimization of the Syringolins Yields Potent Proteasome Inhibitors with Activity Against Leukemia Cell Lines.” Bioorganic & Medicinal Chemistry 23, 18 (September 2015): 6218–6222 © 2015 Elsevier Ltd
Version: Author's final manuscript
ISSN
0968-0896